title: [Laboratory and clinical studies of rokitamycin dry syrup in the field of pediatrics].
abstract: Laboratory and clinical studies on rokitamycin (RKM) dry syrup, a new macrolide antibiotic, were carried out in the field of pediatrics. The results are summarized as follows. 1. Plasma concentrations and urinary recovery rates after oral administration on fasting of RKM dry syrup at doses of 10 mg/kg and 20 mg/kg to 2 and 1 cases, respectively, were determined. Peak plasma levels were obtained in 30 minutes after administration of both dosages with half-lives of 1.5 to 2.2 hours. A clear-cut dose response was observed. Urinary recovery rates in the first 6 hours after administration ranged from 1.75 to 2.26%. 2. The MICs of RKM against 80 clinical isolates (Streptococcus pyogenes 9, Streptococcus pneumoniae 14, Branhamella catarrhalis 4, Haemophilus influenzae 27, Haemophilus parainfluenzae 9, Haemophilus haemolyticus 2, Haemophilus parahaemolyticus 14 and Campylobacter jejuni 1) were compared with MICs of midecamycin acetate (MOM), josamycin (JM) and erythromycin (EM). The antibacterial activity of RKM was superior to those of MOM and JM and slightly inferior to that of EM. 3. Twenty-eight pediatric patients with acute infectious diseases (acute tonsillitis 4, streptococcal infection 4, acute bronchitis 9, pneumonia 4, mycoplasmal pneumonia 2 and Campylobacter enteritis 5) were treated with RKM dry syrup at a daily dose of 12-42.9 mg/kg t.i.d. as a rule. Efficacy rates were 92.9% clinically and 58.6% bacteriologically. 4. No adverse reactions were observed. Abnormal laboratory findings were mild; thrombocytosis in 2 and eosinophilia in 1. 5. The taste and the odor of RKM dry syrup preparation were sufficiently tolerable for the pediatric patients to accept it.
authors.affiliation: Department of Pediatrics, Anjo Kosei Hospital.
authors.forename: K
authors.initials: K
authors.lastname: Kuno
authors.forename: Y
authors.initials: Y
authors.lastname: Nakao
authors.forename: N
authors.initials: N
authors.lastname: Yamamoto
authors.forename: F
authors.initials: F
authors.lastname: Hayakawa
authors.forename: H
authors.initials: H
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Kimura
authors.forename: H
authors.initials: H
authors.lastname: Takeuchi
mesh_terms: D000284:Administration, Oral; D001991:Bronchitis / Q000188:drug therapy / Q000378:metabolism; D002169:Campylobacter Infections / Q000188:drug therapy / Q000378:metabolism; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004751:Enteritis / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007933:Leucomycins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015644:Miocamycin / Q000031:analogs & derivatives*; D011014:Pneumonia / Q000188:drug therapy / Q000378:metabolism; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000378:metabolism; D013290:Streptococcal Infections / Q000188:drug therapy / Q000378:metabolism
chemical_list: D007933:Leucomycins; D015644:Miocamycin; C033383:rokitamycin